To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.
Age ≥ 18 years
Receive B-cell depletion therapy or bendamustine within 6months
Laboratory confirmed SARS-CoV-2 infection
Symptoms onset within 72 hours
Prior use of any anti-SARS-CoV-2 agents within 2 weeks. Remdesivir or NMV/r initiated within 24 hours is acceptable
Life expectancy < 1 month
Previous adverse effect related to remdesivir or NMV/r
Concurrent use medicine with drug-drug interaction with NMV/r
Parallel
combination therapy
DrugA combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
SOC
DrugStandard of care
The proportion of SARS-CoV-2 CT > 30 on Day 14
The proportion of SARS-CoV-2 CT \> 30 on Day 14 of each group.
The proportion of mortality or respiratory failure requiring intubation and mechanical ventilation.
The proportion of mortality or respiratory failure requiring intubation and mechanical ventilation within 28 days after antiviral agent initiation of each group.
The proportion of patients developing anti-viral treatment emerging adverse events.
The proportion of patients developing anti-viral treatment emerging adverse events.
The proportion of secondary bacterial or fungal infection of each group.
The proportion of secondary bacterial or fungal infection of each group.
The proportion of viral rebound within 28 days after antiviral agent initiation.
The proportion of viral rebound within 28 days after antiviral agent initiation of each group.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
